ANNX · Annexon, Inc. · Executive Compensation
$4.10
+0.10 (+2.50%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$817.78M
Shares
204.44M
Volume · Oct 9
2.39M
Avg daily vol (3M)
3.11M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Douglas Love | President & Chief Executive Officer | $3,579,202 |
| Ted Yednock | Executive Vice President and Chief Innovation Officer | $1,379,052 |
| Jennifer Lew | Executive Vice President and Chief Financial Officer | $1,341,274 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Douglas Love | President & Chief Executive Officer | $3,672,746 |
| Jamie Dananberg | Executive Vice President and Chief Medical Officer | $1,564,359 |
| Ted Yednock | Executive Vice President and Chief Innovation Officer | $1,563,793 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Douglas Love | President & Chief Executive Officer | $2,453,184 |
| Rick Artis | Executive Vice President and Chief Scientific Officer | $1,829,232 |
| Ted Yednock | Executive Vice President and Chief Innovation Officer | $1,139,456 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Douglas Love | President & Chief Executive Officer | $3,582,434 |
| Ted Yednock | Executive Vice President and Chief Innovation Officer | $1,477,120 |
| Jennifer Lew | Executive Vice President and Chief Financial Officer | $1,440,415 |
| Michael Overdorf | Executive Vice President and Chief Business Officer | $1,396,668 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Douglas Love | President and Chief Executive Officer | $8,069,473 |
| Larry Mattheakis | Executive Vice President and Chief Scientific Officer | $3,296,856 |
| Ted Yednock | EVP and Chief Innovation Officer | $3,173,316 |
| Sanjay Keswani | Former Executive Vice President and Chief Medical Officer | $3,162,847 |
| Jennifer Lew | Executive Vice President and Chief Financial Officer | $3,127,757 |
| Michael Overdorf | Executive Vice President and Chief Business Officer | $3,082,233 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Douglas Love | President and Chief Executive Officer | $4,602,462 |
| Michael Overdorf | EVP & Chief Business Officer | $3,312,871 |
| Ted Yednock | EVP and Chief Innovation Officer | $2,338,515 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Douglas Love | President and Chief Executive Officer | $3,388,240 |
| Sanjay Keswani | Former Executive Vice President and Chief Medical Officer | $1,620,180 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark S. Blumenkranz | Class II director | Appointed | 2026-08-10 |
| Muneer Satter | member of the board of directors | Resigned | 2026-08-10 |
| William Jones | Class I director | Appointed | 2025-01-10 |
| Dean Richard Artis, Ph.D. | Chief Scientific Officer | Appointed | 2023-01-06 |